Cabaletta Bio's stock is trading at $1.49, up 14.59% in pre-market, driven by positive new Phase 1/2 clinical data for its rese-cel therapy presented at ACR Convergence 2026. - The data, presented on November 8-9, highlighted sustained one-year responses in dermatomyositis patients, and updated clinical and safety findings showing a favorable benefit-risk profile across multiple autoimmune diseases. - This follows a November 5 earnings update where the company set a 1Q 2028 target for a myositis BLA submission.